Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting…
DNA synthesis company Ribbon Biolabs has announced the successful implementation of its InfiniSynth platform for the automated assembly of sequence-agnostic…